Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 7741 AL 7755

Comparing the impact of various exercise modalities on old adults with Alzheimer's disease: A Bayesian network meta-analysis

Hu F, Peng J, Wang W, Shen L, Jia M.

Complement Ther Clin Pract. 2025 May;59:101968. doi: 10.1016/j.ctcp.2025.101968. Epub 2025 Mar 10.

Phytochemical regulation of CaMKII in Alzheimer's disease: A review of molecular mechanisms and therapeutic potential

Lin Z, Sun M.

Pharmacol Res. 2025 Jun;216:107790. doi: 10.1016/j.phrs.2025.107790. Epub 2025 May 21.

Effectiveness of acupuncture combined with donepezil for Alzheimer's disease: A systematic review and meta-analysis

Wu Y, Zhan Y, Zhu W, Pei J.

Medicine (Baltimore). 2025 Jun 6;104(23):e42651. doi: 10.1097/MD.0000000000042651.

Therapeutic implications of allopregnanolone in Alzheimer's related depression

Tidke B, Itekar S, Khobragade R, Vinchurney M, Trivedi R, Taksande B, Umekar M.

Behav Brain Res. 2025 Oct 18;495:115785. doi: 10.1016/j.bbr.2025.115785. Epub 2025 Aug 23.

Effects of cerebellar intermittent theta-burst stimulation on patients with Alzheimer's disease: A randomized controlled trial

Zhang X, Sun Z, Wu D, Shi X, Song C, Guan X, Hao J, Guo Y, Wang X, Wei D, Liu Z, Zhao J, Jiang W.

J Alzheimers Dis. 2025 Oct;107(3):1187-1199. doi: 10.1177/13872877251366656. Epub 2025 Aug 13.

ABBV-552 in patients with mild Alzheimer's disease: a randomized phase IIb trial

Lynch SY, Jia J, Miles N, Boiser J, Buhl DL, Graff O, Zadikoff C.

Alzheimers Dement. 2025 Dec;21(12):e70994. doi: 10.1002/alz.70994.

Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer's disease

Cummings J, Cohen S, Murphy J, Brothers HM, Nejati M, Forrestal F, de Moor C, O'Gorman J, Harrison J, Jaeger J, Mummery CJ, Porsteinsson AP, Potashman M, Tian Y, Yang L, He P, Haeberlein SB.

Alzheimers Dement. 2025 Jun;21(6):e70224. doi: 10.1002/alz.70224.

Home-Based Gamma Transcranial Alternating Current Stimulation in Patients With Alzheimer Disease: A Randomized Clinical Trial

Cantoni V, Casula EP, Tarantino B, Cupidi C, Huber N, Altomare D, Premi E, Zummo E, Esposito R, Leonardi C, Herukka SK, Solje E, Ferrari A, Cotelli MS, Gasparotti R, Martorana A, Fracassi C, Santarnecchi E, Koch G, Haapasalo A, Grassi M, Benussi A, Borroni B.

JAMA Netw Open. 2025 Dec 1;8(12):e2546556. doi: 10.1001/jamanetworkopen.2025.46556.

Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease

Chen CD, Franklin EE, Li Y, Joseph-Mathurin N, Burns AL, Hobbs DA, McCullough AA, Schultz SA, Xiong C, Wang G, Masellis M, Hsiung GR, Gauthier S, Berman SB, Roberson ED, Honig LS, Clarnette R, Ringman JM, Galvin JE, Brooks W, Suzuki K, Black S, Levin J, Aggarwal NT, Jucker M, Frosch MP, Kofler JK, White C 3rd, Keene CD, Chen J, Daniels A, Gordon BA, Ibanez L, Karch CM, Llibre-Guerra J, McDade E, Morris JC, Supnet-Bell C, Allegri RF, Lee JH, Day GS, Lopera F, Roh JH, Schofield PR, Mills S, Benzinger TLS, Bateman RJ, Perrin RJ; DIAN-TU Study Team; DIAN-Obs Study Team.

Acta Neuropathol. 2025 Jun 3;149(1):57. doi: 10.1007/s00401-025-02890-7.

Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study

Boon BDC, Piura YD, Moloney CM, Chalk JL, Lincoln SJ, Rutledge MH, Rothberg DM, Kouri N, Hinkle KM, Roemer SF, Johnson DR, Burkett BJ, Lowe VJ, Petersen RC, Dickson DW, Reichard RR, Nguyen AT, Graff-Radford J, Knopman DS, Graff-Radford NR, Murray ME.

Lancet Neurol. 2025 Nov;24(11):931-944. doi: 10.1016/S1474-4422(25)00313-8.

Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial

Burns JM, Morris JK, Vidoni ED, Wilkins HM, Choi IY, Lee P, Hunt SL, Mahnken JD, Brooks WM, Lepping RJ, Gupta A, Esterline R, Oscarsson J, Swerdlow RH.

Alzheimers Dement. 2025 Jun;21(6):e70416. doi: 10.1002/alz.70416.

Resistance exercise to reduce risk of falls in people with Alzheimer's disease: a randomised clinical trial

Cámara-Calmaestra R, Martínez-Amat A, Aibar-Almazán A, Hita-Contreras F, de Miguel-Hernando N, Rodríguez-Almagro D, Jiménez-García JD, Achalandabaso-Ochoa A.

Physiotherapy. 2025 Mar;126:101440. doi: 10.1016/j.physio.2024.101440. Epub 2024 Oct 28.

Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trials

Su CH, Chang YT, Tseng HS, Kuo CY, Chen JH, Chien PY, Chang YJ, Hung CC.

Clin Med (Lond). 2025 Jul;25(4):100336. doi: 10.1016/j.clinme.2025.100336. Epub 2025 Jun 3.

Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial

Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, Ridha B, Raza S, Livingston NR, Frangou E, Love S, Williams G, Lawrence R, Mcfarlane B, Archer H, Coulthard E, Underwood BR, Koranteng P, Karim S, Bannister C, Perneczky R, Prasanna A, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Holscher C, Mansouri A, Chester-Jones M, Holmes J, Tan T, Williams S, Ashraf A, Brooks DJ, Harrison J, Hinz R, Tadros G, Passmore AP, Ballard C.

Nat Med. 2026 Jan;32(1):353-361. doi: 10.1038/s41591-025-04106-7. Epub 2025 Dec 1.

Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer's disease: A systematic review and meta-analysis

Tonegawa-Kuji R, Hou Y, Hu B, Lorincz-Comi N, Pieper AA, Tousi B, Leverenz JB, Cheng F.

PLoS Med. 2025 Mar 31;22(3):e1004568. doi: 10.1371/journal.pmed.1004568. eCollection 2025 Mar.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias